Skip to main content

Table 4 Comparative analysis between pregnant women in use of NNRTI and PI

From: Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study

  NNRTI PI p* RR CI 95%
n % n %
Co-infections during pregnacy 0.010  
 Yes 111 78.2 515 86.7   0.60 0.44–0.81
 No 31 21.8 79 13.3   1.00  
Obstetrical complications 0.001  
 Yes 57 40.1 334 56.0   0.60 0.44–0.81
 No 85 59.9 262 44.0   1.00  
ART adherence during pregnancy 0.387  
 Yes 121 86.4 494 83.4   1.21 0.78–1.88
 No 19 13.6 98 16.6   1.00  
ART changes during pregnancy < 0.0001  
 Yes 10 7.1 134 22.5   0.31 0.17–0.58
 No 131 92.9 462 77.5   1  
Viral load after ART 0.001  
 Undetectable 57 47.5 365 63.4   1  
 Detectable 63 52.5 211 36.6   1.70 1.23–2.35
Anemia 0.664  
 Yes 73 58.4 323 56.3   1.07 0.78–1.48
 No 52 41.6 251 43.7   1  
Thrombocytopenia 0.479  
 Yes 15 12.1 83 14.5   0.08 0.51–1.38
 No 109 87.9 488 85.5   1  
Hepatic alteration < 0.0001  
 Yes 94 83.2 267 47.8   4.26 2.67–6.81
 No 19 16.8 292 52.2   1  
Dyslipidemia 0.015  
 Yes 52 72.2 406 83.9   0.56 0.35–0.89
 No 20 27.8 78 16.1   1  
Allergic reaction 0.002  
 Yes 10 7.5 11 1.9   2.71 1.69–4.37
 No 123 92.5 578 98.1   1  
Fasting glycemia alteration 0.032  
 Yes 12 11.9 112 21.1   0.55 0.31–0.97
 No 89 88.1 418 78.9   1  
Total 142 100 597 100    
  1. (#) Numbers are different due to the lack of information on some patients
  2. * Chi-square
  3. ART antiretroviral therapy, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor
\